Anti-infectious agents against MRSA

Molecules

Volumn 18, Issue 1, 2013, Pages 204-224

  Koyama, Nobuhiro ^a   Inokoshi, Junji ^a   Tomoda, Hiroshi ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Anti infectious agents; MRSA; Peptidoglycan; Teichoic acid; Virulence factors

Indexed keywords

EID: 84872865982     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18010204     Document Type: Review

References (51)

1. Bugg, T.D.; Braddick, D.; Dowson, C.G.; Roper, D.I. Bacterial cell wall assembly: Still an attractive antibacterial target. Trends. Biotechnol. 2011, 29, 167-173.
2. Giesbrecht, P.; Kersten, T.; Maidhof, H.; Wecke, J. Staphylococcal cell wall: Morphogenesis and fatal variations in the presence of penicillin. Microbiol. Mol. Biol. Rev. 2007, 62, 1371-1414.
3. Tomasz, A. Penicillin-binding proteins and the antibacterial effectiveness of beta-lactam antibiotics. Rev. Infect. Dis. 1986, 8, S260-S278.
4. Hammes, W.P.; Neuhaus, F.C. On the mechanism of action of vancomycin: Inhibition of peptidoglycan synthesis in Gaffkya homari. Antimicrob. Agents Chemother. 1974, 6, 722-728.
5. Ostash, B.; Walker, S. Moenomycin family antibiotics: Chemical synthesis, biosynthesis, and biological activity. Nat. Prod. Rep. 2010, 27, 1595-1617.
6. Stone, K.J.; Strominger, J.L. Mechanism of action of bacitracin: Complexation with metal ion and C55-isoprenyl pyrophosphate. Proc. Natl. Acad. Sci. USA 1971, 68, 3223-3227.
7. Tomasz, A. Multiple-Antibiotic resistant pathogenic bacteria. N. Engl. J. Med. 1994, 330, 1247-1251.
8. Klevens, R.M.; Morrison, M.A.; Nadle, J.; Petit, S.; Gershman, K.; Ray, S.; Harrison, L.H.; Lynfield, R.; Dumyati, G.; Townes, J.M.; et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. J. Am. Med. Assoc. 2007, 298, 1763-1771.
9. Hiramatsu, K.; Hanaki, H.; Ino, T.; Yabuta, K.; Oguri, T.; Tenover, F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 1997, 40, 135-136.
10. Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR Morb. Mortal. Wkly. Rep. 1997, 46, 765-766.
11. Bachmann, B.O.; Li, R.; Townsend, C.A. ß-Lactam synthetase: A new biosynthetic enzyme. Proc. Natl. Acad. Sci. USA 1998, 95, 9082-9086.
12. Shimizu, N.; Koyama, T.; Ogura, K. Molecular cloning, expression, and purification of undecaprenyl diphosphate synthase. No sequence similarity between E- and Z-prenyl diphosphate synthases. J. Biol. Chem. 1998, 273, 19476-19481.
13. Li, H.; Huang, J.; Jiang, X.; Seefeld, M.; McQueney, M.; Macarron, R. The effect of triton concentration on the activity of undecaprenyl pyrophosphate synthase inhibitors. J. Biomol. Screen. 2003, 8, 712-715.
14. Peukert, S.; Sun, Y.; Zhang, R.; Hurley, B.; Sabio, M.; Shen, X.; Gray, C.; Dzink-Fox, J.; Tao, J.; Cebula, R.; Wattanasin, S. Design and structure-Activity relationships of potent and selective inhibitors of undecaprenyl pyrophosphate synthase (UPPS): Tetramic, tetronic acids and dihydropyridin-2-ones. Bioorg. Med. Chem. Lett. 2008, 18, 1840-1844.
15. Kuo, C.J.; Guo, R.T.; Lu, I.L.; Liu, H.G.; Wu, S.Y.; Ko, T.P.; Wang, A.H.; Liang, P.H. Structurebased inhibitors exhibit differential activities against Helicobacter pylori and Escherichia coli undecaprenyl pyrophosphate synthases. J. Biomed. Biotechnol. 2008, 2008, 1-6.
16. Durrant, J.D.; Cao, R.; Gorfe, A.A.; Zhu, W.; Li, J.; Sankovsky, A.; Oldfield, E.; McCammon, J.A. Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-Aided drug design. Chem. Biol. Drug Des. 2011, 78, 323-332.
17. Inokoshi, J.; Nakamura, Y.; Hongbin, Z.; Uchida, R.; Nonaka, K.; Masuma, R.; Tomoda, H. Spirohexalines, New Inhibitors of Bacterial Undecaprenyl Pyrophosphate Synthase, produced by Penicillium brasilianum FKI-3368. J. Antibiot. 2012, doi:10.1038/ja.2012.83.
18. Hashizume, H.; Igarashi, M.; Hattori, S.; Hori, M.; Hamada, M.; Takeuchi, T. Tripropeptins, novel antimicrobial agents produced by Lysobacter sp. I. Taxonomy, isolation and biological activities. J. Antibiot. 2001, 54, 1054-1059.
19. Hashizume, H.; Hirosawa, S.; Sawa, R.; Muraoka, Y.; Ikeda, D.; Naganawa, H.; Igarashi, M. Tripropeptins, novel antimicrobial agents produced by Lysobacter sp. J. Antibiot. 2004, 57, 52-58.
20. Hashizume, H.; Sawa, R.; Harada, S.; Igarashi, M.; Adachi, H.; Nishimura, Y.; Nomoto, A. Tripropeptin C blocks the lipid cycle of cell wall biosynthesis by complex formation with undecaprenyl pyrophosphate. Antimicrob. Agents Chemother. 2011, 55, 3821-3828.
21. Fulco, P.; Wenzel, R.P. Ramoplanin: A topical lipoglycodepsipeptide antibacterial agent. Expert. Rev. Anti Infect. Ther. 2006, 4, 939-945.
22. Walker, S.; Chen, L.; Hu, Y.; Rew, Y.; Shin, D.; Boger, D.L. Chemistry and biology of ramoplanin: A lipoglycodepsipeptide with potent antibiotic activity. Chem. Rev. 2005, 105, 449-476.
23. Vértesy, L.; Ehlers, E.; Kogler, H.; Kurz, M.; Meiwes, J.; Seibert, G.; Vogel, M.; Hammann, P. Friulimicins: Novel lipopeptide antibiotics with peptidoglycan synthesis inhibiting activity from Actinoplanes friuliensis sp. nov. II. Isolation and structural characterization. J. Antibiot. 2000, 53, 816-827.
24. Schneider, T.; Gries, K.; Josten, M.; Wiedemann, I.; Pelzer, S.; Labischinski, H.; Sahl, H.G. The lipopeptide antibiotic Friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. Antimicrob. Agents Chemother. 2009, 53, 1610-1618.
25. Chamberland, S.; Blais, J.; Boggs, A.F.; Bao, Y.; Malouin, F.; Hecker, S.J.; Lee, V.J. MC-207,252 Abolishes PBP2a mediated ß-lactam resistance in Staphylococci. In 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, USA, 14-20 September 1995; pp. F138-F144.
26. Nicolson, K.; Evans, G.; O'Toole, P.W. Potentiation of methicillin activity against methicillinresistant Staphylococcus aureus by diterpenes. FEMS Microbiol. Lett. 1999, 179, 233-239.
27. Zhao, W.H.; Hu, Z.Q.; Okubo, S.; Hara, Y.; Shimamura, T. Mechanism of synergy between epigallocatechin gallate and beta-lactams against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 2001, 45, 1737-1742.
28. Shimizu, M.; Shiota, S.; Mizushima, T.; Ito, H.; Hatano, T.; Yoshida, T.; Tsuchiya, T. Marked potentiation of activity of beta-lactams against methicillin-resistant Staphylococcus aureus by corilagin. Antimicrob. Agents Chemother. 2001, 45, 3198-3201.
29. Shiota, S.; Shimizu, M.; Mizushima, T.; Ito, H.; Hatano, T.; Yoshida, T.; Tsuchiya, T. Restoration of effectiveness of beta-lactams on methicillin-resistant Staphylococcus aureus by tellimagrandin I from rose red. FEMS Microbiol. Lett. 2000, 185, 135-138.
30. Koyama, N.; Nagahiro, T.; Yamaguchi, Y.; Masuma, R.; Tomoda, H.; Omura, S. Stemphones, novel potentiators of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Aspergillus sp. FKI-2136. J. Antibiot. 2005, 58, 695-703.
31. Yamazaki, H.; Koyama, N.; Omura, S.; Tomoda, H. Structure-Activity relationships of stemphones, potentiators of imipenem activity against methicillin-resistant Staphylococcus aureus. J. Antibiot. 2008, 61, 426-441.
32. Fukumoto, A.; Kim, Y.P.; Matsumoto, A.; Takahashi, Y.; Shiomi, K.; Tomoda, H.; Omura, S. Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144. I. Taxonomy, fermentation, isolation and structural elucidation. J. Antibiot. 2008, 61, 1-6.
33. Fukumoto, A.; Kim, Y.P.; Hanaki, H.; Shiomi, K.; Tomoda, H.; Omura, S. Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144. II. Biological activities. J. Antibiot. 2008, 61, 7-10.
34. Koyama, N.; Tokura, Y.; Takahashi, Y.; Tomoda, H. New cyslabdans B and C, potentiators of imipenem activity against methicillin-resistant Staphylococcus aureus produced by Streptomyces sp. K04-0144. Acta. Pharm. Sin. B 2011, 1, 236-239.
35. Yamazaki, H.; Nonaka, K.; Masuma, R.; Omura, S.; Tomoda, H. Xanthoradones, new potentiators of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Penicillium radicum FKI-3765-2: I. Taxonomy, fermentation, isolation and biological properties. J. Antibiot. 2009, 62, 431-434.
36. Yamazaki, H.; Omura, S.; Tomoda, H. Xanthoradones, new potentiators of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Penicillium radicum FKI-3765-2 II. Structure elucidation. J. Antibiot. 2009, 62, 435-437.
37. Huber, J.; Donald, R.G.; Lee, S.H.; Jarantow, L.W.; Salvatore, M.J.; Meng, X.; Painter, R.; Onishi, R.H.; Occi, J.; Dorso, K.; et al. Chemical genetic identification of peptidoglycan inhibitors potentiating carbapenem activity against methicillin-resistant Staphylococcus aureus. Chem. Biol. 2009, 16, 837-848.
38. Shiota, S.; Shimizu, M.; Sugiyama, J.; Morita, Y.; Mizushima, T.; Tsuchiya, T. Mechanisms of action of corilagin and tellimagrandin I that remarkably potentiate the activity of ß-lactams against methicillin-resistant Staphylococcus aureus. Microbiol. Immunol. 2004, 48, 67-73.
39. Koyama, N.; Tokura, Y.; Münch, D.; Sahl, H.-G.; Schneider, T.; Shibagaki, Y.; Ikeda, H.; Tomoda, H. The nonantibiotic small molecule cyslabdan enhances the potency of ß-lactams against MRSA by inhibiting pentaglycine interpeptide bridge synthesis. PLoS One 2012, 7, e48981.
40. Berger-Bächi, B.; Barberis-Maino, L.; Strässle, A.; Kayser, F.H. FemA, a host-mediated factor essential for methicillin resistance in Staphylococcus aureus. Molecular cloning and characterization. Mol. Gen. Genet. 1989, 219, 263-269.
41. Maidhof, H.; Reinicke, B.; Blümel, P.; Berger-Bächi, B.; Labischinski, H. femA, which encodes a factor essential for expression of methicillin resistance, affects glycine content of peptidoglycan in methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains. J. Bacteriol. 1991, 173, 3507-3513.
42. Strandén, A.M.; Ehlert, K.; Labischinski, H.; Berger-Bächi, B. Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J. Bacteriol. 1997, 179, 9-16.
43. Brown, S.; Meredith, T.; Swoboda, J.; Walker, S. Staphylococcus aureus and Bacillus subtilis W23 make polyribitol wall teichoic acids using different enzymatic pathways. Chem. Biol. 2010, 17, 1101-1110.
44. Swoboda, J.G.; Campbell, J.; Meredith, T.C.; Walker, S. Wall teichoic acid function, biosynthesis, and inhibition. Chembiochem 2010, 11, 35-45.
45. Swoboda, J.G.; Meredith, T.C.; Campbell, J.; Brown, S.; Suzuki, T.; Bollenbach, T.; Malhowski, A.J.; Kishony, R.; Gilmore, M.S.; Walker, S. Discovery of a small molecule that blocks wall teichoic acid biosynthesis in Staphylococcus aureus. ACS Chem. Biol. 2009, 4, 875-883.
46. Schirner, K.; Stone, L.K.; Walker, S. ABC transporters required for export of wall teichoic acids do not discriminate between different main chain polymers. ACS Chem. Biol. 2011, 6, 407-412.
47. Lee, K.; Campbell, J.; Swoboda, J.G.; Cuny, G.D.; Walker, S. Development of improved inhibitors of wall teichoic acid biosynthesis with potent activity against Staphylococcus aureus. Bioorg. Med. Chem. Lett. 2010, 20, 1767-1770.
48. Pelz, A.; Wieland, K.P.; Putzbach, K.; Hentschel, P.; Albert, K.; Götz, F. Structure and biosynthesis of staphyloxanthin from Staphylococcus aureus. J. Biol. Chem. 2005, 280, 32493-32498.
49. Liu, G.Y.; Essex, A.; Buchanan, J.T.; Datta, V.; Hoffman, H.M.; Bastian, J.F.; Fierer, J.; Nizet, V. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J. Exp. Med. 2005, 202, 209-215.
50. Liu, C.I.; Liu, G.Y.; Song, Y.; Yin, F.; Hensler, M.E.; Jeng, W.Y.; Nizet, V.; Wang, A.H.; Oldfield, E. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 2008, 319, 1391-1394.
51. Sakai, K.; Koyama, N.; Fukuda, T.; Mori, Y.; Onaka, H.; Tomoda, H. Search method for inhibitors of Staphyloxanthin production by methicillin-resistant Staphylococcus aureus. Biol. Pharm. Bull. 2012, 35, 48-53.